Asian equities traded mixed on Monday as a cautious sentiment set in after fresh conflict in Ukraine at the weekend.» Read More
April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.
April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.
LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.
March 31- Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.
March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.
*Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.
CHICAGO, March 10- While it is hard to knock the advice of Warren Buffett, whose annual letter to Berkshire Hathaway Inc shareholders recently lofted down from the mountain of capitalism, some of his tips can be tweaked.
The biotech drug lebrikizumab, which was developed by Roche Holding's Genentech unit, was tested at three doses in patients whose asthma was not sufficiently controlled even with high-dose, inhaled corticosteroids and a second asthma-controlling therapy.
CHICAGO, March 3- While the euro zone presents the unalluring face of sluggish growth, that doesn't mean it should be neglected. The reason for the negativity stems from concerns over conflict in Ukraine and reported euro zone growth at 0.3 percent in the fourth quarter.
An upbeat handover from Wall Street on Thursday inspired gains in most Asian shares on Friday.
Sunday's vote in Switzerland has raised fears that the measure is the latest in a long list of reforms that could curb the country's business-friendly environment.
Swiss voters on Sunday narrowly backed proposals to reintroduce immigration quotas with the European Union, Swiss television reported.
Global healthcare company Roche is confident of growth in emerging markets despite the economic slowdown.
But the delay in packaging the liquid version has not affected supplies of regular Tamiflu, said the Roche unit that makes the medication.
European equities closed lower on Tuesday as investors remained cautious over the timing of the Fed's reduction of its stimulus program.
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
European equities closed narrowly higher on Thursday, with investors underwhelmed by U.S. lawmakers finally reaching a deal to lift the country's borrowing limit.
Emerging markets still offer room for growth, Roche's CEO told CNBC after the pharma posted an 8 percent increase in third-quarter sales.
With Washington's debt battle over, markets will quickly shift focus to earnings and how much the government shutdown actually impacted the economy.
Andrew Weiss, head of pharma and biotech research at Vontobel, says Roche's plan reflects the Swiss pharmaceutical giant's strong pipeline.